What was the overall market valuation of the US syringomyelia market in 2024?

The overall market valuation was $45.86 Million in 2024. Read More

What is the projected market valuation for the US syringomyelia market by 2035?

The projected valuation for 2035 is $123.55 Million. Read More

What is the expected CAGR for the US syringomyelia market during the forecast period 2025 - 2035?

The expected CAGR for the market during this period is 9.43%. Read More

Which companies are considered key players in the US syringomyelia market?

Key players include Roche, Novartis, Bristol-Myers Squibb, Pfizer, Sanofi, AstraZeneca, Merck & Co., Teva Pharmaceutical Industries, and Eli Lilly and Company. Read More

What are the market segments for the US syringomyelia market based on type?

The market segments based on type include Congenital Syringomyelia and Acquired Syringomyelia. Read More

What were the valuations for Congenital and Acquired Syringomyelia in 2024?

In 2024, Congenital Syringomyelia was valued at $18.34 Million, while Acquired Syringomyelia was valued at $27.52 Million. Read More

What diagnostic methods are utilized in the US syringomyelia market?

Diagnostic methods include Magnetic Resonance Imaging (MRI) and Computerized Tomography (CT) Scan. Read More

What were the valuations for MRI and CT Scan in 2024?

In 2024, MRI was valued at $20.0 Million, and CT Scan was valued at $15.0 Million. Read More

What treatment options are available in the US syringomyelia market?

Treatment options include Monitoring, Surgical Care, and Medication. Read More

What were the valuations for Surgical Care and Medication in 2024?

In 2024, Surgical Care was valued at $20.0 Million, while Medication was valued at $15.86 Million. Read More

US Syringomyelia Market

ID: MRFR/MED/18505-HCR

100 Pages

Vikita Thakur

Last Updated: April 06, 2026

US Syringomyelia Market Research Report By Type (Congenital syringomyelia, Acquired syringomyelia), By Diagnosis (Magnetic resonance imaging (MRI), Computerized tomography (CT) scan, Others), By Treatment (Monitoring, Surgical care, Medication, Chiari surgery, Expansive duraplasty, Surgical removal of the obstruction, Draining the syrinx (shunt operation), Analgesics, Muscle relaxants, Others) and By End User (Hospitals, Clinics, Diagnostic centers, Drug stores, Pharmacies, Others) - Growth & Industry Forecast 2025 To 2035

US Syringomyelia Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)9.43%

2024 Market Size$ 45.86 Million

2025 Market Size$ 50.19 Million

2035 Market Size$ 123.55 Million

Key Players

Roche

Novartis

Bristol-Myers Squibb

Pfizer

Sanofi

AstraZeneca

Trends

Technological Advancements in Treatment
Increased Awareness and Education
Research and Development Initiatives

Opportunities

Rising Incidence of Syringomyelia
Advancements in Diagnostic Techniques
Rising Demand for Personalized Medicine

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Chemicals and Materials, BY Type (USD Million)
  1. 4.1.1 Congenital Syringomyelia
  2. 4.1.2 Acquired Syringomyelia
2. 4.2 Chemicals and Materials, BY Diagnosis (USD Million)
  1. 4.2.1 Magnetic Resonance Imaging (MRI)
  2. 4.2.2 Computerized Tomography (CT) Scan
  3. 4.2.3 Others
3. 4.3 Chemicals and Materials, BY Treatment (USD Million)
  1. 4.3.1 Monitoring
  2. 4.3.2 Surgical Care
  3. 4.3.3 Medication
4. 4.4 Chemicals and Materials, BY End User (USD Million)
  1. 4.4.1 Hospitals
  2. 4.4.2 Clinics
  3. 4.4.3 Diagnostic Centers
  4. 4.4.4 Drug Stores
  5. 4.4.5 Pharmacies
  6. 4.4.6 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Chemicals and Materials
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Roche (CH)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Novartis (CH)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Bristol-Myers Squibb (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Pfizer (US)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Sanofi (FR)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 AstraZeneca (GB)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Merck & Co. (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Teva Pharmaceutical Industries (IL)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
  9. 5.2.9 Eli Lilly and Company (US)
    1. 5.2.9.1 Financial Overview
    2. 5.2.9.2 Products Offered
    3. 5.2.9.3 Key Developments
    4. 5.2.9.4 SWOT Analysis
    5. 5.2.9.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE
3. 6.3 US MARKET ANALYSIS BY DIAGNOSIS
4. 6.4 US MARKET ANALYSIS BY TREATMENT
5. 6.5 US MARKET ANALYSIS BY END USER
6. 6.6 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF CHEMICALS AND MATERIALS
9. 6.9 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
10. 6.10 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
11. 6.11 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
12. 6.12 CHEMICALS AND MATERIALS, BY TYPE, 2024 (% SHARE)
13. 6.13 CHEMICALS AND MATERIALS, BY TYPE, 2024 TO 2035 (USD Million)
14. 6.14 CHEMICALS AND MATERIALS, BY DIAGNOSIS, 2024 (% SHARE)
15. 6.15 CHEMICALS AND MATERIALS, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
16. 6.16 CHEMICALS AND MATERIALS, BY TREATMENT, 2024 (% SHARE)
17. 6.17 CHEMICALS AND MATERIALS, BY TREATMENT, 2024 TO 2035 (USD Million)
18. 6.18 CHEMICALS AND MATERIALS, BY END USER, 2024 (% SHARE)
19. 6.19 CHEMICALS AND MATERIALS, BY END USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY DIAGNOSIS, 2025-2035 (USD Million)
  3. 7.2.3 BY TREATMENT, 2025-2035 (USD Million)
  4. 7.2.4 BY END USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

US Chemicals and Materials Market Segmentation

Chemicals and Materials By Type (USD Million, 2025-2035)

Congenital Syringomyelia
Acquired Syringomyelia

Chemicals and Materials By Diagnosis (USD Million, 2025-2035)

Magnetic Resonance Imaging (MRI)
Computerized Tomography (CT) Scan
Others

Chemicals and Materials By Treatment (USD Million, 2025-2035)

Monitoring
Surgical Care
Medication

Chemicals and Materials By End User (USD Million, 2025-2035)

Hospitals
Clinics
Diagnostic Centers
Drug Stores
Pharmacies
Others

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”